The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global neurothrombectomy devices market exhibited moderate growth during 2015-2020. A neurothrombectomy is performed to retrieve or destroy blood clots in the cerebral neurovasculature using laser, mechanical and ultrasound technologies. It is primarily used for rapid achievement of recanalization, and increasing efficiency to treat large vessel occlusions and lowering the risk of hemorrhagic events. It also assists in minimizing the mortality rate among patients and improving functional outcomes. As a result, neurothrombectomy devices are extensively utilized in the treatment of acute ischemic stroke (AIS) across the globe.
According to the World Health Organization (WHO), stroke represents one of the leading causes of dementia and depression across the globe. It results in the sudden death of brain cells on account of the lack of oxygen. As neurothrombectomy devices aid in destroying blood clots, increasing blood supply to the brain and decreasing the mortality rate, the rising instances of AIS, particularly among the geriatric population, are positively influencing the growth of the market. Additionally, due to the rapid product approval process, leading manufacturers are introducing technologically advanced variants. For instance, Medtronic PLC launched its fourth-generation Solitaire X revascularization device in April 2019 for the treatment of AIS. This device features an optimized delivery system for improved efficiency while also retaining the technical features. Similarly, Vesalio obtained Conformite Europeenne (CE) mark approval for NeVa, an advanced neurothrombectomy device, in May 2019 and introduced an optimized delivery system for efficient results. This device relies on the DropZone and Smart Marker technology and features characteristics like a distal filter. Other factors, including the increasing adoption of unhealthy lifestyles and the escalating demand for minimally invasive surgeries by individuals, are anticipated to foster the market growth. Looking forward, IMARC Group expects the global neurothrombectomy devices market to grow at a CAGR of 5.7% during the forecast period (2021-2026).
IMARC Group provides an analysis of the key trends in each sub-segment of the global neurothrombectomy devices market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product and end use.
Breakup by Product:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Acandis GmbH, Argon Medical (Weigao Group), Edwards Lifesciences Corporation, Johnson & Johnson, Koninklijke Philips N.V., Medtronic Plc, Penumbra Inc., Phenox GmbH, Stryker Corporation, Teleflex Incorporated, Terumo Corporatio and Vesalio LLC.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at